about
DNA damage, homology-directed repair, and DNA methylationCandidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington's disease motor onsetPopulation stratification may bias analysis of PGC-1α as a modifier of age at Huntington disease motor onset.Ganglioside GM1 induces phosphorylation of mutant huntingtin and restores normal motor behavior in Huntington disease miceTractography of the corpus callosum in Huntington's disease.Changes of peripheral TGF-β1 depend on monocytes-derived macrophages in Huntington diseaseDefective Sphingosine-1-phosphate metabolism is a druggable target in Huntington's disease.Nitric oxide dysregulation in platelets from patients with advanced Huntington disease.Impairment of blood-brain barrier is an early event in R6/2 mouse model of Huntington Disease.Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6/2 mouse model.Reduced bioavailable manganese causes striatal urea cycle pathology in Huntington's disease mouse model.FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease.Impaired ganglioside metabolism in Huntington's disease and neuroprotective role of GM1.Mutant Huntingtin induces activation of the Bcl-2/adenovirus E1B 19-kDa interacting protein (BNip3)Impaired Levels of Gangliosides in the Corpus Callosum of Huntington Disease Animal ModelsMotor phenotype is not associated with vascular dysfunction in symptomatic Huntington's disease transgenic R6/2 (160 CAG) miceResistin impairs insulin-evoked vasodilation.Pressure-induced vascular oxidative stress is mediated through activation of integrin-linked kinase 1/betaPIX/Rac-1 pathway.β-amyloid inhibits protein prenylation and induces cholesterol sequestration by impairing SREBP-2 cleavage.Terapeutic Potential of Microencapsulated Sertoli Cells in Huntington Disease.MRI measures of corpus callosum iron and myelin in early Huntington's disease.Assessment of Blood-brain Barrier Permeability by Intravenous Infusion of FITC-labeled Albumin in a Mouse Model of Neurodegenerative Disease.Tumor necrosis factor-alpha mediates hemolysis-induced vasoconstriction and the cerebral vasospasm evoked by subarachnoid hemorrhage.Enhanced expression of Harvey ras induced by serum deprivation in cultured astrocytes.Glyco-sphingo biology: a novel perspective for potential new treatments in Huntington's disease.Disease-modifying effects of ganglioside GM1 in Huntington's disease models.Neuromedin U potentiates ADP- and epinephrine-induced human platelet activation.Beta-amyloid deposition in brain is enhanced in mouse models of arterial hypertension.Nebivolol induces nitric oxide release in the heart through inducible nitric oxide synthase activation.The p85 regulatory subunit of PI3K mediates TSH-cAMP-PKA growth and survival signals
P50
Q21092492-18FD0B6E-C1D8-43B7-B8ED-D25BF8E19F0DQ30416270-593C55C9-8427-4F69-9356-E2612A92890FQ30424048-55806F1F-DFA7-4534-B478-654D61283507Q30506469-9C1E7423-50CC-44CE-9346-58D594E67824Q31137452-D95363ED-A76F-4579-BE6D-84A5D13988B3Q33644718-9FE68866-CAE2-4019-A236-08E42F2B6052Q33902931-EE266DBD-2372-43FD-938C-8430D687B15AQ35107991-ACDD1FA8-D725-41D6-8307-327FAA9BE89CQ38766477-34B300AF-4C2E-48F7-95C9-48B371467E64Q38861728-2727FBFD-1405-4EA7-85F8-38D644601F29Q38954727-51575387-1BD9-43A5-ADF3-55B4418D5ADAQ39049796-FA046FDA-E9A6-4C2B-8C7D-2331AE95D735Q39726453-7F05B631-DB01-4A29-BA89-B99F0E7E18B4Q39757740-69A51594-25F9-4466-A7EF-2F328B5A7CF5Q41340916-2F4F33A5-3E18-4DB5-BF21-3656D488C0A8Q41842714-1163C24A-BD8C-4EF2-95DD-FCE606D20997Q42522267-98BB0102-88A6-4126-952E-374352B058FDQ43273401-345AA846-E4E1-48E6-BA4B-64F5AE1B6926Q43846570-A8B81DA0-6F41-4FEF-8870-FA3198C1333DQ45295362-40884E76-00D3-4ACA-A671-F4FC5FA89B18Q45299568-A808A4F1-F989-4C06-93DE-CBE266529774Q45305588-1904F4D9-6366-4D63-8DBD-2D8BFB96CF84Q45995798-9DAD8997-F19F-48DD-9B78-AE6B9970C133Q46646136-825F4967-37A6-45DC-BFBA-58631FDC181FQ47098894-700FAE7F-B272-462D-B77D-B1122F9EFFCEQ47154575-8A05CDC3-8CE3-43F3-AD20-0FD89BABC3E8Q47594904-A2C31CFB-6641-41BC-BAF6-F887A1929B69Q48087176-E7691E0E-FA79-4FA6-8E38-94C785E4900FQ54323997-88DECB2A-398A-42AC-A0E8-F0B8982AF322Q79251505-C077A1C1-F968-416A-8046-79E1356E3122
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Alba Di Pardo
@ast
Alba Di Pardo
@en
Alba Di Pardo
@es
Alba Di Pardo
@nl
Alba Di Pardo
@sl
type
label
Alba Di Pardo
@ast
Alba Di Pardo
@en
Alba Di Pardo
@es
Alba Di Pardo
@nl
Alba Di Pardo
@sl
prefLabel
Alba Di Pardo
@ast
Alba Di Pardo
@en
Alba Di Pardo
@es
Alba Di Pardo
@nl
Alba Di Pardo
@sl
P106
P1153
23980160500
P21
P31
P496
0000-0002-9514-0086